Skip to content

Should GB virus be used as a therapeutic vaccine to slow HIV progression?

Uganda: Food insecurity decreases after starting ART

Diarrhoea remains a common problem in people with HIV

Low bone density present in young men taking HIV therapy

Four-class, five-drug regimen given to monkeys shows signs of producing long-term viral load reductions off treatment

Second-line HIV therapy effective and durable in South Africa, and adherence support could improve rates of viral suppression

The road to PrEP: trials, regulation and roll-out

Active injecting drug users must be provided with adherence support when they start HIV therapy

Is treatment as prevention ready to roll out, or do we need to know more?